FMP
Sep 12, 2024 7:57 PM - Davit Kirakosyan(Last modified: Sep 13, 2024 1:55 AM)
Image credit: FMP
Moderna (NASDAQ:MRNA) saw its stock tumble over 19% intra-day on Thursday following the company’s announcement of significant reductions to its research and development (R&D) budget.
At its annual R&D Day, the biotech firm disclosed plans to scale back R&D spending by approximately $1.1 billion. The company aims to reduce projected R&D expenses from $4.8 billion in 2024 to a range of $3.6 billion to $3.8 billion by 2027.
This move is part of Moderna’s broader strategy to shift its focus from new R&D initiatives toward maximizing the potential of its current product pipeline and driving commercial growth. CEO emphasized that while the company has made considerable strides in mRNA vaccine and therapeutic development, it now needs to concentrate on bringing existing products to market.
The CEO acknowledged the company’s strong track record in advancing R&D, with a success rate exceeding industry standards at every stage. However, he noted that Moderna’s late-stage pipeline, along with the complexities of product launches, necessitates slowing down on new investments to prioritize delivering ten new products by 2027.
Among these upcoming products are a next-generation COVID-19 vaccine and a combined flu/COVID vaccine, both expected to receive approval in 2024. Moderna is also making progress in areas such as oncology and rare diseases.
Despite the planned budget cuts, Moderna underscored its high success rate in clinical trials, with a 66% combined probability of success—well above the industry average of 19%.
However, the decision to reduce R&D spending has unsettled investors, contributing to the sharp decline in the company’s stock price.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...
May 27, 2024 3:30 PM - Rajnish Katharotiya
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...